1. Introduction {#sec1}
===============

The clinical use of doxorubicin (DOX), an anthracycline antibiotic, can have both favorable and unfavorable consequences. On the one hand, DOX is one of the most potent antitumor agents available; on the other hand, its use is limited by development of dose-dependent cardiomyopathy involving cardiomyocyte apoptosis and myocardial fibrosis that may lead to congestive heart failure usually refractory to common medications \[[@B1]\]. Although there is a linear relationship between the cumulative dose received and the incidence of cardiotoxicity, cardiotoxicity may develop in some patients at doses below the generally accepted threshold level \[[@B2]\]. Considerable research has focused on elucidating the mechanisms of DOX-induced cardiomyopathy, aiming at finding ways to prevent the development of cardiotoxicity. Several mechanisms have been reported, including generation of free radicals and lipid peroxidation of cardiac membranes \[[@B3]\], myocyte damage induced by cardiac calcium overload \[[@B4]\], formation of DOX-iron complex \[[@B5]\], impaired myocardial adrenergic regulation, cellular toxicity of anthracycline metabolites \[[@B6]\], and inhibition of beta-oxidation of long chain fatty acids with the consequent depletion of cardiac ATP \[[@B7]\].

Because of the undisputed key role that DOX plays in the treatment of many neoplastic diseases, one of the research aims being pursued most intensively is the possibility of eliminating its cardiotoxicity or reducing it to an acceptable level. If the cardiac complications resulting from DOX could be prevented or at least reduced, higher doses could potentially be utilized, thereby increasing cancer cure rates. In this regard, various drugs, including L-carnitine \[[@B8]\], dexrazoxane \[[@B9]\], vitamin E \[[@B10]\], melatonin \[[@B11]\], and resveratrol \[[@B12]\], have been shown to protect against DOX-induced cardiotoxicity. Noticeably, a common theme among these therapeutic approaches is that free radical generation by DOX is being targeted. This highlights the critical role of oxidative stress in DOX-induced cardiac toxicity. This is supported by the findings demonstrating that DOX induces cardiomyocyte apoptosis by reactive oxygen species-dependent mechanism \[[@B6], [@B13]\]. Interestingly, this pathway has been found to be distinct from apoptosis induced by DOX in tumor cells \[[@B14]\].

The prevalence of glucose intolerance is increased in patients with malignancy \[[@B15]\]. Marks and Bishop \[[@B16]\] have reported that patients with malignant disease had a significantly lower net rate of disappearance of glucose, compared with the control subjects. In addition, DOX itself, at therapeutic doses, has been reported to be highly toxic to endocrine function mainly on insulin secretion \[[@B17]\]. Moreover, glucocorticoids are often included with other agents in cancer treatment to prevent side effects \[[@B18], [@B19]\]. However, administration of glucocorticoids is commonly associated with impairment of insulin sensitivity, elevations in peripheral glucose levels, and the suppression of the hypothalamic-pituitary-adrenal axis \[[@B20]\]. Insulin resistance is correlated with an enhanced risk for cancer. In addition, the rate of tumor recurrence, metastatic spread, and fatal outcome is higher in cancer patients with hyperglycemia or type II diabetes, as compared with tumor patients without metabolic disease \[[@B21]\]. Taken together, all these previously mentioned findings emphasize the need for an adjuvant drug to be given along with DOX to patients with malignancy, in order to improve glucose tolerance and prevent DOX-induced cardiotoxicity.

Metformin (MET) is an oral biguanide antihyperglycemic drug that is widely used for the management of type 2 diabetes mellitus. Therapeutic effects of MET have been attributed to a combination of improved peripheral uptake and utilization of glucose, decreased hepatic glucose output, decreased rate of intestinal absorption of carbohydrates, and enhanced insulin sensitivity \[[@B22], [@B23]\]. Beyond its glucose-lowering effects, MET has been shown to exhibit antioxidant properties in various tissues, an effect that is independent of its effect on insulin sensitivity and acts to decrease lipid peroxidation \[[@B24], [@B25]\]. Further, MET has been demonstrated to exert cardioprotective effects that could be due to its direct beneficial effects on cellular and mitochondrial function and therefore be independent of its insulin-sensitizing effect \[[@B26]\]. Noteworthy, MET has been recently shown to significantly improve left ventricular function and survival via activation of AMP-activated protein kinase (AMPK) in an *in vivo* murine model of heart failure \[[@B27]\].

Based on the aforementioned information, we hypothesized that MET, by virtue of its antioxidant and cardioprotective effects, can protect against DOX-induced cardiomyopathy. The overall objective of the present study was to determine the extent to which MET can protect against DOX-induced-energy starvation and mitochondrial damage and to determine the possible mechanism of this protection. Results from this study may shed the light on the usefulness of MET, as a safe, clinically approved drug, in such pathological situations.

2. Materials and Methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

Adult male Wistar albino rats, weighing 230--250 g, were obtained from the Animal Care Center, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. Animals were housed in metabolic cages under controlled environmental conditions (25°C and a 12 h light/dark cycle). Animals had free access to pulverized standard rat pellet diet. The protocol of this study has been approved by the Research Ethics Committee of College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

2.2. Chemicals {#sec2.2}
--------------

DOX was a generous gift from the King Khalid University Hospital drug store. MET, acetyl-CoA, CoA-SH, adenosine triphosphate, and adenosine diphosphate were purchased from Sigma Chemical Company (St. Louis, MO, USA). TRIzol reagent was purchased from Invitrogen Co. (Grand Island, NY, USA). The high-capacity cDNA reverse transcription kits and SYBR Green PCR Master Mix were purchased from Applied Biosystems (Foster City, CA, USA). Metformin was dissolved in normal saline and administered orally at low dose (100 mg/kg) and high dose (500 mg/kg). All other chemicals were of the highest commercially available analytical grade.

2.3. Experimental Design and Treatment Protocol {#sec2.3}
-----------------------------------------------

In this study, the DOX treatment regimen used to develop the cumulative cardiotoxicity was adopted from Beanlands et al. \[[@B28]\] and Sayed-Ahmed et al. \[[@B29]\], while MET dosages (50 and 500 mg/kg, p.o.) were selected based on studies by Anurag and Anuradha \[[@B30]\] and Wang et al. \[[@B31]\], respectively. A total of 60 adult male Wistar albino rats were randomly divided into 6 groups of 10 animals each. In the first group, animals were injected intraperitoneally (i.p.) with normal saline (2.5 mL/kg) and served as a normal control. Animals in the second group were injected, every other day, with DOX (3 mg/kg, i.p.) over a period of 11 days to obtain cumulative dose of 18 mg/kg. Animals in the third and fourth groups received MET (50, 500 mg/kg, p.o., daily), respectively, over a period of 11 days. Animals in the fifth group were injected every other day with DOX (3 mg/kg, i.p.) as in group 2 and daily treated with MET (50 mg/kg, p.o.) over a period of 11 days. Animals in group 6 were injected every other day with DOX (3 mg/kg, i.p.) as in group 2 and daily treated with MET (500 mg/kg, p.o.) over a period of 11 days. Twenty-four hours after receiving the last dose of DOX, animals were anesthetized with light ether anesthesia, and blood samples were obtained from the retro-orbital sinus of the eye. Serum was separated for measurement of lactate dehydrogenase (LDH) and creatine phosphokinase iso-enzyme MB (CK-MB). Immediately after collection of blood samples, animals were sacrificed and hearts were quickly excised, washed with saline, blotted with a filter paper, and homogenized as indicated in the procedures of measurement of each parameter, using a Branson homogenizer (250, VWR Scientific, Danbury, CT., USA).

2.4. Assessment of Serum Levels of Cardiac Enzymes {#sec2.4}
--------------------------------------------------

Serum levels of LDH and CK-MB were determined according to the methods of Buhl and Jackson \[[@B32]\] and Wu and Bowers \[[@B33]\], respectively.

2.5. Determination of CoA-SH and Acetyl-CoA in Isolated Rat Heart Mitochondria {#sec2.5}
------------------------------------------------------------------------------

Free CoA-SH and acetyl-CoA were determined in isolated rat heart mitochondria using HPLC as described previously \[[@B34]\]. Briefly, mitochondria were mixed with ice-cold 6% perchloric acid and centrifuged at 300 ×g for 5 min at 0.5°C. The resulting supernatant fluid was neutralized to pH 6-7 and then injected into the HPLC apparatus. Chromatographic separation was performed using ODS-Hypersil, 150 × 4.6 mm i.d., 5 *μ*m column (Supelco SA, Gland, Switzerland). The UV detector was adjusted at 254 nm and set at 0.005. A mobile phase of 220 mM potassium phosphate, containing 0.05% dithioglycol (A) and 98% methanol/2% chloroform (B), was used. The flow rate was 0.6 mL/min, and the gradient was as follows: at zero time, 94% A and 6% B; at 8 min, 92% A and 8% B; at 14 min, 87% A and 13% B; at 25 min, 80% A and 20% B; at 40 min, 55% A and 45% B; at 60 min, 94% A and 6% B.

2.6. Measurement of Adenosine Triphosphate in Cardiac Tissue {#sec2.6}
------------------------------------------------------------

Adenosine triphosphate (ATP) was determined in heart tissues using high-performance liquid chromatography (HPLC) as described by Botker et al. \[[@B35]\]. In brief, heart tissue was homogenized in ice-cold 6% perchloric acid and centrifuged at 3000 rpm for 15 min at 0.5°C, and the supernatant fluid was injected into the HPLC system (Kontron Instrument, Milano, Italy) after neutralization to pH 6-7. Chromatographic separation was performed at a flow rate of 1.2 mL/min, using ODS-Hypersil, 150 × 4.6 mm I.D., 5 *μ*m column (Supelco SA, Gland, Switzerland) and 75 mM ammonium dihydrogen phosphate as the mobile phase. The peak elution was followed at 254 nm.

2.7. Determination of Reduced Glutathione in Cardiac Tissues {#sec2.7}
------------------------------------------------------------

Cardiac tissue levels of the acid-soluble thiols, mainly reduced glutathione (GSH), were assayed spectrophotometrically at 412 nm, according to the method of Ellman \[[@B36]\]. The contents of GSH were expressed as *μ*mol/g wet tissue.

2.8. Histopathology and Electron Microscopy {#sec2.8}
-------------------------------------------

The heart tissues from all studied groups of rats were analyzed at both histopathological and electron microscopic levels. Three-micron thick sections were performed on the formalin-fixed, paraffin-embedded tissue of the heart, and the sections were stained with routine hematoxylin and eosin stains (H&E). The sections were studied under the optic routine microscope by the histopathologists involved in the study.

The heart tissues submitted for electron microscopy examination were fixed in 3% glutaraldehyde. The tissues were embedded in osmium tetroxide, and the semithin sections were stained with toluidine blue. The adequacy of the sample in each case was checked on the semithin sections. The thin sections were stained with uranyl acetate and lead citrate, then all the sections were examined and photographed by the same histopathologists.

2.9. RNA Preparation and Quantitative Real-Time PCR {#sec2.9}
---------------------------------------------------

To determine the effect of DOX and/or MET on mRNA expression levels of cardiac hypertrophic gene markers (*α*-MHC and *β*-MHC) and oxidative stress-mediated genes (glutathione S-transferase-*α* (GST*α*), catalase (CAT), NAD(P)H:quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1)), we conducted quantitative real-time polymerase chain reaction (qRT-PCR), as follows.

### 2.9.1. RNA Extraction and cDNA Synthesis {#sec2.9.1}

Total RNA from the heart tissue homogenate was isolated using TRIzol reagent (Invitrogen) according to the manufacturer\'s instructions and quantified by measuring the absorbance at 260 nm; the RNA quality was determined by measuring the 260/280 ratio. Thereafter, first strand cDNA synthesis was performed using the high-capacity cDNA reverse transcription kit (Applied Biosystems), according to the manufacturer\'s instructions. Briefly, 1.5 *μ*g of total RNA from each sample was added to a mix of 2.0 *μ*L of 10x reverse transcriptase buffer, 0.8 *μ*L of 25x dNTP mix (100 mM), 2.0 *μ*L of 10x reverse transcriptase random primers, 1.0 *μ*L of MultiScribe reverse transcriptase, and 3.2 *μ*L of nuclease-free water. The final reaction mix was kept at 25°C for 10 min, heated to 37°C for 120 min, heated for 85°C for 5 s, and finally cooled to 4°C.

### 2.9.2. Quantification of mRNA Expression by qRT-PCR {#sec2.9.2}

Quantitative analysis of mRNA expression of target genes was performed by RT-PCR through subjecting the resulting cDNA to PCR amplification using 96-well optical reaction plates in the ABI Prism 7500 System (Applied Biosystems). The 25 *μ*L reaction mix contained 0.1 *μ*L of 10 *μ*M forward primer and 0.1 *μ*L of 10 *μ*M reverse primer (40 nM final concentration of each primer), 12.5 *μ*L of SYBR Green Universal Master Mix, 11.05 *μ*L of nuclease-free water, and 1.25 *μ*L of cDNA sample. The primers used in the current study are listed in [Table 1](#tab1){ref-type="table"}. Assay controls were incorporated onto the same plate, namely, no-template controls to test for the contamination of any assay reagents. The real-time PCR data were analyzed using the relative gene expression (i.e., ΔΔCT) method, as described in Applied Biosystems User Bulletin no. 2. Briefly, the data are presented as the fold change in gene expression normalized to the endogenous reference gene *β*-actin and relative to a calibrator.

2.10. Statistical Analysis {#sec2.10}
--------------------------

The data are expressed as mean ± standard error of the mean (SEM). The significance of differences among groups was evaluated with one-way analysis of variance (ANOVA) followed by the Tukey-Kramer multiple comparison test. *P* values of 0.05 or less were considered significant.

3. Results {#sec3}
==========

3.1. MET Protects against DOX-Induced Cardiac Myocyte Injury {#sec3.1}
------------------------------------------------------------

[Table 2](#tab2){ref-type="table"} shows the effects of DOX, MET, and DOX plus MET on the serum level of cardiotoxicity enzymatic indices, CK-MB and LDH, in rats. Administration of DOX (3 mg/kg) every other day over a period of 11 days resulted in a significant 240% and 280% increases in serum LDH and CK-MB, respectively, as compared to the control group. Treatment with MET at dose level either 50 mg/kg or 500 mg/kg for 11 successive days showed nonsignificant changes as compared to the control group. Interestingly, daily administration of MET (500 mg/kg) to DOX-treated rats resulted in a complete reversal of DOX-induced increase in serum CK-MB and LDH to the control values. However, administration of the small dose of MET (50 mg/kg) did not prevent DOX-induced increase in cardiac enzymes.

3.2. MET Rescues the Myocardium from DOX-Induced Depletion of Intramitochondrial CoA-SH {#sec3.2}
---------------------------------------------------------------------------------------

The effects of DOX, MET, and DOX plus MET on the level of CoA-SH and acetyl-CoA in isolated rat heart mitochondria are shown in [Table 3](#tab3){ref-type="table"}. Treatment with DOX resulted in a significant 42% decrease in CoA-SH level and a significant 66% increase in acetyl-CoA in isolated rat heart mitochondria as compared to the control group. Treatment with MET (500 mg/kg) alone resulted in a significant 30% and 123% increase in CoA-SH level and a significant 40% and 45% decrease in acetyl-CoA as compared to the control and DOX groups, respectively. Interestingly, daily administration of the high dose of MET (500 mg/kg) to DOX-treated rats resulted in a complete prevention of DOX-induced decrease in CoA-SH and increase in acetyl-CoA to the control values.

3.3. MET Protects the Myocardium against DOX-Induced Energy Starvation {#sec3.3}
----------------------------------------------------------------------

[Figure 1](#fig1){ref-type="fig"} shows the effects of DOX, MET, and DOX plus MET on ATP level in cardiac tissues. Treatment with a total cumulative dose of DOX (18 mg/kg) resulted in a significant decrease (31.5%) in ATP level in cardiac tissues as compared to the control group. However, treatment with MET (500 mg/kg) for 11 successive days caused a significant increase (54%) in ATP as compared to the control group. Interestingly, daily administration of MET (500 mg/kg) to DOX-treated rats resulted in a complete reversal of DOX-induced decrease in ATP to the control values. However, administration of the small dose of MET (50 mg/kg) did not alter DOX-induced decrease in ATP level in cardiac tissues.

3.4. MET Reverses the Effect of DOX on Cardiac GSH Level {#sec3.4}
--------------------------------------------------------

[Figure 2](#fig2){ref-type="fig"} shows the effects of DOX, MET, and DOX plus MET on GSH level in rat cardiac tissues. Treatment with a total cumulative dose of DOX (18 mg/kg) resulted in a significant 57% decrease in GSH level, as compared to the control group. Treatment with MET at dose level either 50 mg/kg or 500 mg/kg for 11 successive days resulted in a significant and dose-dependent (70% and 102%) increase in GSH level, respectively, as compared to the control group. Daily administration of MET either 50 mg/kg or 500 mg/kg to DOX-treated rats resulted in a complete reversal of DOX-induced decrease in cardiac GSH level to the control values.

3.5. Histopathology and Electron Microscopy {#sec3.5}
-------------------------------------------

The light microscopic examination of the normal control rat hearts showed normal architecture and cytological features ([Figure 3(i)](#fig3){ref-type="fig"}). However, examination of the heart tissues of DOX-alone-treated rats revealed focal mild inflammation of the myocardium (arrows in [Figure 3(ii)](#fig3){ref-type="fig"}) that was associated with myocardial fiber injury, in addition to vacuolar changes of the cytoplasm of some myocardial cells (arrow in [Figure 3(ii)](#fig3){ref-type="fig"} B). The inflammatory infiltrate consisted of lymphocytes, plasma cells, and histiocytes, with prominent mononuclear chronic inflammatory appearance that replaced the degenerated myocardial muscle fibers with apparent hypereosinophilia ([Figure 3(ii)](#fig3){ref-type="fig"} A and B). Treatment with MET alone (50 or 500 mg/kg) showed no pathological changes in the tested heart tissues, while, in the group that received MET (50 mg/kg) and DOX, the heart tissues showed few mild inflammatory foci with undetected myocardial injury ([Figure 3(iii)](#fig3){ref-type="fig"} A and B). The heart tissues of the rats that received MET (500 mg/kg) and DOX revealed almost normal morphological tissue appearance without any detected inflammation or tissue injury ([Figure 3(iv)](#fig3){ref-type="fig"} A and B).

The electron microscopic examination of normal control rat hearts revealed normal mitochondria (arrow in [Figure 4(i)](#fig4){ref-type="fig"} A) with preserved internal architectures and surrounding organized myofibrils (arrow in [Figure 4(i)](#fig4){ref-type="fig"} B). The heart tissues of DOX-treated rats exhibited a prominent component of patchy myofibrillar loss and disarray, in addition to prominent hypercontraction bands with prominent A band loss ([Figure 4(ii)](#fig4){ref-type="fig"} A and B). Moreover, the mitochondria showed remarkable abnormalities that included enlargement, contour irregularities, increased spacing between the cristae and disruption of the internal architecture (arrow in [Figure 4(ii)](#fig4){ref-type="fig"} B). The group of rats treated with 50 mg/kg or 500 mg/kg of MET illustrated no significant ultrastructural changes. Hearts of rats treated with MET (50 mg/kg) and DOX showed some focal but prominent pathological findings. In this focus, there was an evidence of loss of myofibrils in addition to mitochondrial size and shape variation and many dilated lysosomes (arrow in [Figure 4(iii)](#fig4){ref-type="fig"} A). On the contrary, a significant improvement was seen in the ultrastructure of the hearts of rats treated with MET 500 mg/kg and DOX ([Figure 4(iv)](#fig4){ref-type="fig"} A and B). The examined sections showed a normal mitochondrial size and shape with normal arrangement of cristae.

3.6. MET Reverses DOX-Mediated Changes in the Levels of Cardiac Hypertrophic Genes {#sec3.6}
----------------------------------------------------------------------------------

To investigate the effect of MET on the expression of cardiac hypertrophic gene markers, *α*-MHC and *β*-MHC mRNA levels were determined in both healthy and DOX-induced cardiotoxic rats using RT-PCR. [Figure 5](#fig5){ref-type="fig"} shows that both doses of MET did not significantly alter the mRNA expression of both *α*-MHC and *β*-MHC. On the other hand, DOX-treated rats showed a significant decrease in the mRNA level of *α*-MHC by approximately 40%, whereas *β*-MHC mRNA level was induced dramatically 250%. Importantly, administration of MET significantly restored DOX-mediated changes in hypertrophic genes, which was more pronounced at the highest dose (500 mg/kg).

3.7. MET Restores DOX-Mediated Changes in the Levels of Oxidative Stress-Related Genes {#sec3.7}
--------------------------------------------------------------------------------------

To further explore the role of oxidative stress in the cardioprotective effect of MET, we have investigated the effect of MET on the expression of four oxidative stress-mediated genes, GST*α*, CAT, NQO1, and HO-1. [Figure 6](#fig6){ref-type="fig"} showed that induction of cardiotoxicity by DOX was associated with upregulated expression of GST*α* (A) and HO-1 (B) which was accompanied with a significant decrease in CAT (C) and NQO1 (D) mRNA expression levels as compared to control rats. Although treatment of control rats with MET did not alter the expression of most target genes, treatment of DOX-treated rats with MET significantly restored the DOX-induced modulations of all tested genes in a dose-dependent manner, in that MET induced NQO1 and CAT whereas inhibited GST*α* and HO-1 mRNA expression in a dose-dependent manner.

4. Discussion {#sec4}
=============

The most common hypothesis for the mechanism of DOX-induced cardiac injury is the increase of oxidative stress. Free radical generation by DOX, which is usually associated with a depression of GSH in heart tissue, results in disruption of cellular membrane integrity. This hypothesis is supported by the several reports that have shown that antioxidants, including vitamins E and A, resveratrol, and selenium, protect cardiomyocytes against the toxicity of DOX \[[@B37]\]. On the other hand, impairment of cardiac high-energy phosphate metabolism has been recognized as an important feature of both acute and chronic DOX cardiotoxic action. These energetic deficits have been associated with compromised mitochondrial function \[[@B38]\]. In this context, oxidative damage to cardiac mitochondria and to cardiomyocytes has been widely implicated as a primary cause for doxorubicin-induced cardiac toxicity \[[@B39], [@B40]\]. The enhanced generation of ROS by DOX may directly damage mitochondria or alter the synthesis of proteins associated with the mitochondrial electron transport chain, with the subsequent inhibition of oxidative phosphorylation and decrease in cardiac high-energy phosphate homeostasis \[[@B41], [@B42]\]. The accumulation of various deficiencies in high-energy phosphate metabolism may be a very critical step for the DOX-induced deterioration of cardiac function and for the onset of chronic clinical cardiotoxicity \[[@B43]\].

The model utilized in the present study has already been established in previous publications that included biomarkers of cardiotoxicity as those reported by Beanlands et al. 1994 \[[@B28]\] and Sayed-Ahmed et al. 2010 \[[@B29]\]. In the latter study, rats were injected every other day with doxorubicin (3 mg/kg, i.p.), to obtain treatments with cumulative doses of 6, 12, and 18 mg/kg. The cumulative cardiotoxicity of DOX was clearly featured in that study by the dose-dependent increase in serum cardiac enzymes CK-MB and LDH. At the highest cumulative dose, 18 mg/kg, DOX resulted in a significant increase in CK-MB and LDH and decrease in ATP as well as the expression of apoptotic genes, as compared to the control group. That is why we decided to use that same highest cumulative dose to produce the model of DOX-induced cardiotoxicity on the cellular and molecular levels, rather than functional ones, using the same animal species.

Since DOX causes disruption of cardiac myocyte cell membranes, the release of intracellular proteins, such as LDH and CK-MB, into serum has been used to assay for the presence and extent of cardiac myocyte injury \[[@B6], [@B44]\]. The levels of these two enzymes were markedly increased by DOX administration in our study. Our results are in a good agreement with previous reports \[[@B45], [@B46]\]. In addition, histopathological investigation of cardiac tissues from DOX-treated rats showed myocardial mononuclear chronic inflammation that replaced the degenerated muscle fibers affected. Electron microscopic examination revealed the presence of morphological evidences of mitochondrial injury, as well as myofibrillar loss and disruption. Moreover, treatment with DOX increased *β*-MHC expression and decreased *α*-MHC expression, as a result of cardiac toxicity. This is consistent with earlier published data \[[@B47]--[@B50]\]. All these biochemical and molecular changes and histopathological deteriorations were completely prevented by MET therapy (500 mg/kg, every day). These results suggest that MET therapy during DOX treatment for cancer offers substantial protection of the heart against DOX-induced injury. The initial damage caused by DOX is believed to be oxidative in nature. This drug can undergo one electron reduction to the corresponding semiquinone, leading to the generation of superoxide radical \[[@B51]\]. DOX interacts with iron, generating a DOX-ferric iron free radical complex, and the resulting complex catalyzes the conversion of hydrogen peroxide to the highly reactive hydroxyl radical. Hydrogen peroxide, lipid peroxides, superoxide radical, and hydroxyl radical can damage membranes, macromolecules, and mitochondria and may cause direct myocardial injury \[[@B2], [@B51]\]. Notably, mammalian hearts are vulnerable to DOX cardiotoxicity due to limited antioxidant mechanisms that could protect them from oxidative injury \[[@B2], [@B52]\].

In the present study, total content of GSH, the most important endogenous antioxidant, was assessed as a marker for oxidative stress, since reduced GSH normally represents more than 90% of cellular GSH content \[[@B53]\]. The method used in this study utilized Ellman\'s reagent which determines total SH-containing compounds, which are mainly represented as reduced GSH \[[@B54], [@B55]\]. Also, the gene expression of the oxidative stress molecular markers, NQO-1, catalase, HO-1, and GST-*α*, has been investigated to elaborate more on the oxidative stress pathway. Moreover, it has been reported that DOX itself causes the disappearance of glutathione peroxidase and significantly lowers the levels of GSH in heart tissue. This diminishes the capability of the heart to dispose of hydrogen peroxide, making the heart more susceptible to redox injury \[[@B51], [@B52], [@B56], [@B57]\]. Cardiac tissue level of GSH was demonstrated in our study to be significantly decreased by DOX treatment, which comes in agreement with the previous report by Aleisa et al. \[[@B58]\]. Remarkably, this decrease was completely prevented by the two doses (50 and 500 mg/kg/d) of MET, indicating its strong antioxidant activity and its potential cardioprotective efficacy against DOX cardiotoxicity.

DOX also exerted dramatic effects on the expression of molecular oxidative stress markers. It induced the expression of GST*α* and HO-1 genes and decreased CAT and NQO1 mRNA expression as compared to control rats. DOX treatment is known to enhance the production of the highly reactive lipid peroxidation product 4-hydroxy-2-nonenal (HNE) in cardiac tissue \[[@B59]\]. DOX-induced HNE has been shown to be partially detoxified by conjugation with GSH by GST to form the glutathione conjugate of HNE (GS-HNE) \[[@B60]\]. Induction of GST*α* gene expression by DOX in the present work reveals that cardiac tissues were defending themselves against DOX toxicity by augmenting the expression of GST*α* which, in turn, consumed GSH to detoxify DOX. This is evidenced by the significant decrease of cardiac tissue level of GSH by DOX ([Figure 2](#fig2){ref-type="fig"}). By virtue of its antioxidant activity, MET released the pressure on cardiac tissue to augment GST*α* expression, thereby saving the cardiac levels of GSH ([Figure 2](#fig2){ref-type="fig"}).

Moreover, the results showed that CAT, an enzyme responsible for the removal of H~2~O~2~, gene expression is decreased by DOX treatment, supporting the idea that DOX induces a state of oxidative stress in the heart tissues. NQO1 is cytosolic enzyme that plays an essential role in the detoxification of quinones through two-electron reduction process \[[@B61], [@B62]\]. In addition, NQO1 helps to maintain endogenous antioxidants, in their active form \[[@B63]\]. It seems that the decrease in NQO1 expression by DOX treatment in our study is attributed to a direct inhibitory effect. This may lead to insufficient NQO1 activity that could have buffered DOX-oxidizing properties. Therefore, the heart was highly exposed to oxidizing species induced by DOX. In the same sense, DOX induced HO-1 gene expression which is the rate-limiting enzyme of heme degradation, and it is a stress-responsive protein that responds to many kinds of chemically or physiologically produced oxidative stress, including GSH depletion, in various cells and tissues \[[@B64], [@B65]\]. Hence, the induction of HO-1 gene expression by DOX could be understood as a response of cardiac cells to DOX-induced GSH depletion. MET, alone or along with DOX, decreased HO-1 expression. This could be because MET itself possesses a significant antioxidant activity as shown above. The significant increase in the GSH level and CAT and NQO-1 mRNA expression in heart tissue of animals after treatment with MET supports the above hypothesis that MET ameliorates DOX-induced oxidative stress. These results have extended earlier finding by others that MET substantially increased GSH level in normal rats \[[@B24]\] and protected against the DOX-induced decrease of GSH in mice \[[@B58]\]. Interestingly, Faure et al. \[[@B24]\] showed that this effect was independent of MET effect on insulin activity. More recently, Asensio-Lopez et al. \[[@B66]\] illustrated that MET exerts a protective effect against DOX-induced cardiotoxicity through the involvement of the cardiac system of adiponectin and restoring the activity of antioxidant enzymes in isolated cardiomyocytes *in vitro*.

The most important role of mitochondria in the myocardium is to supply cardiac cells with ATP, a crucial source of energy for contraction and for the maintenance of ion homeostasis, protein synthesis, and other important cellular functions \[[@B67]\]. In that regard, DOX was shown to inhibit long-chain fatty acid oxidation in the heart \[[@B68]\]. Under physiological conditions, long-chain fatty acids are the favored substrates for energy production in the heart \[[@B69]\]. Consequently, inhibition of long-chain fatty acid oxidation results in a deficiency in ATP supply and accumulation of toxic intermediates including long-chain fatty acyl-CoA thioesters and long-chain acyl-carnitine derivatives in cardiac tissues, with subsequent cardiomyopathy and congestive heart failure \[[@B70]--[@B72]\]. In the present study, level of ATP in cardiac tissue was markedly reduced by DOX treatment. In addition, DOX significantly decreased level of CoA-SH, an indispensable activator in most of the energy-providing systems (TCA cycle, fatty acid oxidation) \[[@B73]\], and increased that of acetyl-CoA, the main product of *β*-oxidation of fatty acids. Acetyl-CoA is a strong inhibitor of 3-ketoacyl-CoA thiolase, the enzyme catalyzing the last step in *β*-oxidation of fatty acids, especially at low concentrations of CoA-SH \[[@B74]\]. Therefore, in the present study, raising the acetyl-CoA/CoA-SH ratio in isolated rat heart mitochondria by DOX could inhibit fatty acid oxidation, with subsequent deleterious effects on cardiac energy supply. Therapy with MET prevented the decrease of ATP and the increase of acetyl-CoA/CoA-SH ratio induced by DOX. These data indicate that MET protects myocardium against DOX-induced energy starvation and depletion of intramitochondrial CoA-SH. In that context, Gundewar et al. \[[@B27]\] have recently reported that MET significantly improves left ventricular function and survival via activation of AMPK in a murine model of heart failure. Activated AMPK phosphorylates a variety of intracellular proteins to increase ATP generation and decrease ATP utilization for processes not immediately critical for survival \[[@B75]\].

Collectively, the data presented in this study suggest that liberation of free radicals induced by DOX treatment causes oxidative injury to heart tissues and organelles including mitochondria. Since heart is almost entirely dependent on ATP generated by mitochondria for its function and contractility \[[@B76]\], mitochondrial injury, with its subsequent depression of myocardial ATP, contributes to the progression of cardiac toxicity \[[@B77]\]. The oxidative injury to the heart is accentuated by the reduction of the cardiac antioxidant defense, represented by the great reduction of GSH content and CAT and NQO-1 gene expression induced by DOX. Therefore, our data suggest that the protective effect of MET against DOX-induced cardiac toxicity could originate from its antioxidant activity.

5. Conclusion {#sec5}
=============

Results from the present investigation reveal that DOX induces its cardiotoxicity by decreasing cardiac level of CoA-SH and increasing that of acetyl-CoA, with the consequent inhibition of fatty acid oxidation and ATP generation. This is aggravated by the increased susceptibility of the heart to oxidant injury due to DOX-induced reduction of cardiac GSH level, as well as the decrease in CAT and NQO-1 gene expression. Our findings demonstrate that MET prevents all of these biochemical and molecular changes and other histopathological and ultrastructural deteriorations in the cardiac tissues, warranting its coadministration with DOX to ameliorate its cardiotoxicity.
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![MET protects the myocardium against DOX-induced energy starvation. Rats (*n* = 10/per treatment type) received normal saline, DOX in a total cumulative dose of 18 mg/kg, MET (50 or 500 mg/kg, p.o., daily), or DOX plus either dose of MET. 24 h after receiving the last dose of DOX, ATP was determined in heart tissues using HPLC. Data are presented as mean ± SEM (*n* = 10). ∗ and \# indicate significant change from control and DOX, respectively, at *P* \< 0.05 using ANOVA followed by the Tukey-Kramer as a post-ANOVA test.](OXIMED2012-434195.001){#fig1}

![MET reverses the effect of DOX on cardiac GSH level. Rats (*n* = 10/treatment type) received normal saline, DOX in a total cumulative dose of 18 mg/kg, MET (50 or 500 mg/kg, p.o., daily) or DOX plus either dose of MET. 24 h after receiving the last dose of DOX, cardiac tissue level of GSH was determined in rat cardiac tissues. Data are presented as mean ± SEM (*n* = 10). ∗ and \# indicate significant change from control and DOX, respectively, at *P* \< 0.05 using ANOVA followed by the Tukey-Kramer as a post-ANOVA test.](OXIMED2012-434195.002){#fig2}

![MET protects myocardium against DOX-induced histopathological deteriorations. Photos (i) A and B show normal cardiac structure derived from normal control rat. Photos (ii) A and B are derived from heart section of a rat treated with a total cumulative dose of 18 mg/kg DOX and shows myocardial fiber injury as vacuolar changes of the cytoplasm and inflammatory infiltrate consisting of lymphocytes, plasma cells and histiocytes (arrow). Photos (iii) A and B show heart sections derived from a rat treated with MET 50 mg/kg prior to a total cumulative dose of 18 mg/kg DOX. It shows few inflammatory foci with considerable improvement in heart histology. Photos (iv) A and B illustrate heart sections obtained from a rat pretreated with MET 500 mg/kg before a total cumulative dose of 18 mg/kg DOX, revealing almost normal histology with a marked improvement in heart histology. Magnification, 400x in A; 100x in B.](OXIMED2012-434195.003){#fig3}

![MET protects myocardium against DOX-induced ultrastructural deteriorations. Photos (i) A and B show normal ultrastructure of a normal control rat heart. Photos (ii) A and B are EM photo taken for a heart section from a rat treated with a total cumulative dose of 18 mg/kg DOX and show a prominent component of patchy myofibrillar loss and disarray, hypercontraction bands with prominent A band loss. They also show mitochondrial abnormalities, including enlargement and irregular contour. Photos (iii) A and B are photos of ultrastructure of rat heart treated with MET 50 mg/kg prior to a total cumulative dose of 18 mg/kg DOX and show mild improvement in the mitochondrial structure. Photos (iv) A and B are photos of ultrastructure of cardiac muscle derived from a rat treated with MET 500 mg/kg prior to a total cumulative dose of 18 mg/kg DOX, showing almost normal ultrastructure, size, and shape of the myocardial fibers. Magnification, low power in A; high power in B.](OXIMED2012-434195.004){#fig4}

![MET reverses DOX-mediated changes in the levels of cardiac hypertrophic genes. Rats (*n* = 10/treatment type) received normal saline, DOX in a total cumulative dose of 18 mg/kg, MET (50 or 500 mg/kg, p.o., daily), or DOX plus either dose of MET. 24 h after receiving the last dose of DOX, total RNA was isolated from rat cardiac tissue using TRIzol methods and quantified spectrophotometrically at 260 nm. The mRNA levels of *α*-MHC (a) and *β*-MHC genes (b) were quantified using RT-PCR and normalized to *β*-actin housekeeping gene. Values represent mean of fold change ± SEM (*n* = 10). \**P* \< 0.05 compared with control rats. ^+^*P* \< 0.05 compared with DOX-treated rats.](OXIMED2012-434195.005){#fig5}

![MET restores DOX-mediated changes in the levels of oxidative stress-related genes. Rats (*n* = 10/treatment type) received normal saline, DOX in a total cumulative dose of 18 mg/kg, MET (50 or 500 mg/kg, p.o., daily), or DOX plus either dose of MET. 24 h after receiving the last dose of DOX, total RNA was isolated from rat cardiac tissue using TRIzol methods and quantified spectrophotometrically at 260 nm. The mRNA levels of GST*α* (a), HO-1 (b), CAT (c), and NQO1 (d) were quantified using RT-PCR and normalized to *β*-actin housekeeping gene. Values represent mean of fold change ± SEM (*n* = 10). \**P* \< 0.05 compared with control rats. ^+^*P* \< 0.05 compared with DOX-treated rats.](OXIMED2012-434195.006){#fig6}

###### 

Primers sequences used for real-time PCR reactions.

  Primer set   Sense primer 5′ → 3′     Antisense primer 5′ → 3′
  ------------ ------------------------ --------------------------
  *α*-MHC      GGACCACCCATCCTCACTTT     AGCCTCTCATCTCGCATCTC
  *β*-MHC      ACCGCTGAGACAGAGAATGG     GGGTTGGCTTGGATGATTT
  GST*α*       GCTTTACTGTGCAAGGGAGACA   GGAAGGAGGATTCAAGTCAGGA
  CAT          CCCGAGTCCAGGCTCTTCT      CGGCCTGTACGTAGGTGTGA
  NQO1         CGCAGACCTTGTGATATTCCAG   TGTTGCGCTCAATCTCCTCCT
  HO-1         ATGGCCTCCCTGTACCACATC    CGTTTCTTCCATCCTTCCAGG
  *β*-Actin    CTGGCACCCAGGACAATG       GCCGATCCACACGGAGTA

###### 

The protective effect of MET against DOX-induced cardiac myocyte injury.

  Treatment group     CK-MB (U/L)    LDH (U/L)
  ------------------- -------------- --------------
  Control             331 ± 16       342 ± 35
  DOX                 1125 ± 94\*    1299 ± 122\*
  MET, 50 mg/kg       342 ± 24^\#^   375 ± 25^\#^
  MET, 500 mg/kg      349 ± 36^\#^   354 ± 32^\#^
  DOX + MET, 50 mg    903 ± 69\*     1030 ± 67\*
  DOX + MET, 500 mg   439 ± 47^\#^   417 ± 36^\#^

All data represent mean values ± SEM (*n* = 10).

\*indicates significant change from control, at *P* \< 0.05.

^\#^indicates significant change from DOX, at *P* \< 0.05.

###### 

MET rescues the myocardium from DOX-induced depletion of intramitochondrial CoA-SH.

  Treatment groups       CoA-SH (nmol/mg protein)   Acetyl-CoA (nmol/mg protein)
  ---------------------- -------------------------- ------------------------------
  Control                3.26 ± 0.16                13.41 ± 0.62
  DOX                    1.89 ± 0.24\*              22.31 ± 0.89\*
  MET, 50 mg/kg          2.91 ± 0.29^\#^            12.19 ± 0.59^\#^
  MET, 500 mg/kg         4.22 ± 0.20^∗\#^           8.01 ± 0.40^∗\#^
  DOX + MET, 50 mg/kg    2.77 ± 0.16                19.28 ± 0.93\*
  DOX + MET, 500 mg/kg   3.06 ± 0.18^\#^            15.44 ± 0.78^\#^

All data represent mean values ± SEM (*n* = 10).

\*indicates significant change from control, at *P* \< 0.05.

^\#^indicates significant change from DOX, at *P* \< 0.05.
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